IL-17A & IL-17F

IL-17A & IL-17F 詳細

英語名Interleukin-17F市販薬剤の数0
治験薬の数5ターゲットの別称Cytokine ML-1,Interleukin-17F,IL17F,Interleukin 17F,IL-17F,CANDF6,ML-1,ML1
研究&開発段階NDA/BLA
英語名Interleukin-17F
ターゲットの別称Cytokine ML-1,Interleukin-17F,IL17F,Interleukin 17F,IL-17F,CANDF6,ML-1,ML1
市販薬剤の数0
治験薬の数5
研究&開発段階NDA/BLA

IL-17A & IL-17F 製品リスト

  • 属性

    Protein (3)

  • 製品ライブラリ

    オンライン (3)

  • 種

    Human (2)Mouse (1)

  • タグ

    His Tag & Avi Tag (1)His Tag & Strep Tag (1)His Tag (1)

  • マーカー

    Biotin-labeled (1)Unconjugated (2)

IL-17A & IL-17Fバックグランド

Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

IL-17A & IL-17F分子の別称

IL-17A,Interleukin-17A,CTLA-8,IL-17,IL-17F,Interleukin-17F,Cytokine ML-1,IL17A&IL17F

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
SonelokimabALX-0761; MSB-0010841; M-1095Phase 3 ClinicalAblynx NvArthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis
詳細
DMT-310DMT-310Phase 3 ClinicalDermataAcne Vulgaris; Rosacea
詳細
ORKA-002ORKA-002; PR-029; ORKA-021Phase 2 ClinicalParagon Therapeutics IncArthritis, Psoriatic; Plaque psoriasis; Psoriasis
詳細
PN-881PN-881Phase 1 ClinicalProtagonist Therapeutics IncDermatitis; Psoriasis
詳細
HY-1770HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770Phase 1 ClinicalSuzhou Pharmavan Co LtdDermatitis, Atopic; Plaque psoriasis
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報